What are the signs, symptoms, and appropriate treatment options for bacterial vaginosis?

Bacterial Vaginosis: Signs, Symptoms, and Treatment

For symptomatic bacterial vaginosis in non-pregnant women, treat with metronidazole 500 mg orally twice daily for 7 days, metronidazole gel 0.75% intravaginally once daily for 5 days, or clindamycin cream 2% intravaginally at bedtime for 7 days—these are equally effective first-line options. 1

Clinical Presentation

Key Symptoms and Signs

BV presents with a characteristic constellation of findings, though up to 50% of women meeting diagnostic criteria are asymptomatic 1:

• Thin, homogeneous white discharge that smoothly coats the vaginal walls (not inflammatory)
• Fishy odor, particularly noticeable after intercourse or during menses
• Vaginal pH >4.5
• Notably, BV does not cause vulvar inflammation or irritation—if these are present, consider alternative diagnoses 1

Pathophysiology

BV results from replacement of normal H₂O₂-producing Lactobacillus species with high concentrations of anaerobic bacteria (Prevotella, Mobiluncus), Gardnerella vaginalis, and Mycoplasma hominis 1, 2. This is the most prevalent cause of vaginal discharge or malodor in reproductive-age women 1.

Diagnosis

Use clinical (Amsel) criteria requiring 3 of 4 findings 1, 2:

1. Homogeneous white noninflammatory discharge coating vaginal walls
2. Clue cells on microscopic examination (epithelial cells with adherent bacteria)
3. Vaginal pH >4.5
4. Positive whiff test (fishy odor before or after adding 10% KOH)

Alternative diagnostic methods:

• Gram stain (Nugent scoring) is acceptable but not required for clinical practice
• Do NOT culture G. vaginalis —it lacks specificity as it's present in 50% of normal women 3
• Newer NAAT and DNA probe tests are available but not necessary for routine diagnosis 1

Treatment Approach

Non-Pregnant Women

First-line regimens (equally efficacious) 1:

• Metronidazole 500 mg orally twice daily for 7 days (cure rate ~84%)
• Metronidazole gel 0.75% intravaginally once daily for 5 days (cure rate ~75-84%)
• Clindamycin cream 2% intravaginally at bedtime for 7 days (cure rate ~82%)

The oral and intravaginal metronidazole regimens show similar efficacy. Clindamycin cream appears slightly less efficacious than metronidazole regimens 1.

Alternative regimens (lower efficacy) 1:

• Metronidazole 2 g orally single dose (cure rate ~84%, but less effective than 7-day regimen)
• Clindamycin 300 mg orally twice daily for 7 days
• Clindamycin ovules 100 g intravaginally at bedtime for 3 days

Critical counseling points:

• Avoid alcohol during metronidazole treatment and for 24 hours after completion (disulfiram-like reaction)
• Clindamycin cream is oil-based and weakens latex condoms and diaphragms 1

Pregnant Women

All symptomatic pregnant women require treatment to relieve symptoms and potentially reduce adverse pregnancy outcomes (premature rupture of membranes, preterm labor, preterm birth, postpartum endometritis) 1.

Recommended regimens for pregnancy 1:

• Metronidazole 250 mg orally three times daily for 7 days
• Clindamycin 300 mg orally twice daily for 7 days

Avoid topical clindamycin cream in pregnancy—three trials showed increased adverse events (prematurity, neonatal infections) with vaginal clindamycin 1. Multiple studies confirm metronidazole does not cause teratogenic or mutagenic effects despite animal data concerns 1, 2.

High-risk pregnant women (prior preterm delivery) with asymptomatic BV may benefit from screening and treatment at first prenatal visit, as this reduced preterm delivery in 3 of 4 randomized trials 1.

Special Considerations

When to Treat Asymptomatic BV

Treat asymptomatic BV before:

• Surgical abortion (reduces post-abortion PID by 50-75%) 1
• Hysterectomy (reduces post-operative infections by 10-75%) 1
• In high-risk pregnant women with prior preterm delivery 1

Do NOT routinely treat:

• Asymptomatic low-risk pregnant women (insufficient evidence) 4
• Before other invasive procedures (more data needed) 1

Recurrent BV

Recurrence is common—over 50% within 6 months 1, 5. For recurrent disease:

• Use any of the recommended regimens again
• Do NOT treat male partners—multiple trials show no benefit for preventing recurrence 1, 2
• No long-term maintenance regimen is currently recommended 1
• Consider newer approaches like Lactobacillus crispatus products (emerging evidence) 6, 7

Allergy/Intolerance

• If metronidazole allergy: use clindamycin cream or oral clindamycin 1
• If metronidazole intolerance: metronidazole gel may be tolerated (lower systemic absorption—<2% of oral dose) 2
• Never give metronidazole vaginally to patients with true metronidazole allergy 1

Common Pitfalls

1. Do NOT culture G. vaginalis for diagnosis—it's not specific 1, 2
2. Do NOT treat partners—this does not prevent recurrence 1, 2
3. Do NOT use single-dose metronidazole as first-line—it has lower efficacy 1
4. Do NOT use topical clindamycin in pregnancy—associated with adverse neonatal outcomes 1
5. Follow-up is unnecessary if symptoms resolve 1

Clinical Significance

BV increases risk for:

• HIV and other STI acquisition 1
• Post-abortion and post-hysterectomy infections 1
• Pelvic inflammatory disease (BV flora recovered from endometrium/salpinges) 2
• Adverse pregnancy outcomes 1, 4